SCHEDULE: MAK Capital Reports 7.8% Stake in ClearPoint Neuro

MAK Capital Fund LP, MAK Capital One LLC, and Michael A. Kaufman have jointly filed a Schedule 13G/A, reporting beneficial ownership of 2,375,861 shares, representing 7.8% of ClearPoint Neuro, Inc.'s common stock.

Summary

• MAK Capital Fund LP, MAK Capital One LLC, and Michael A. Kaufman have jointly filed an amended Schedule 13G, reporting their beneficial ownership of ClearPoint Neuro, Inc. common stock.
• As of June 30, 2026, the reporting persons collectively beneficially owned 2,375,861 shares of common stock.
• This ownership stake represents 7.8% of the total outstanding shares.
• The total outstanding shares of ClearPoint Neuro, Inc. common stock were reported as 30,504,227 as of July 27, 2026, according to the Issuer's Form 10-Q filed on August 3, 2026.
• MAK Capital Fund LP is a Bermuda limited partnership, MAK Capital One LLC is a Delaware limited liability company, and Michael A. Kaufman is a U.S. citizen.
• The filing is an amendment (Amendment No. 2) to a previous Schedule 13G filing.
• The reporting persons certify that the securities were not acquired or held for the purpose of influencing control of the issuer.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a neutral to slightly negative score due to the passive nature of the filing, indicating a change in beneficial ownership without necessarily implying a strategic shift or strong conviction. The filing primarily reports existing holdings and does not signal aggressive accumulation or divestment.

Positives

• The filing confirms a significant institutional ownership stake (7.8%) in ClearPoint Neuro, Inc., which can indicate investor confidence.
• The reporting persons are established entities (MAK Capital Fund LP, MAK Capital One LLC) and an individual (Michael A. Kaufman), suggesting a degree of stability in the shareholder base.

Negatives

• The filing is a Schedule 13G, which is an 'initial beneficial ownership' filing for passive investors, suggesting no active control or strategic intent beyond holding the shares.
• The ownership percentage of 7.8% is substantial but does not represent a controlling stake.

Risks

• Potential for future changes in beneficial ownership by MAK Capital entities, which could impact share price if significant buying or selling occurs.
• The passive nature of the filing means there's no indication of strategic initiatives or support from these significant shareholders.

Future Outlook

The filing itself does not contain forward-looking statements or guidance from ClearPoint Neuro, Inc. It solely reports the beneficial ownership of MAK Capital entities.

Management Comments

• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under 240.14a-11."
• "After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct."

Industry Context

StockSavvy.ai notes that Schedule 13G filings are common for institutional investors who acquire a significant stake but do not intend to take control of the company. This filing places MAK Capital among the larger shareholders of ClearPoint Neuro, Inc., a company operating in the medical technology sector, specifically in neurosurgery.

Stakeholder Impact

• Shareholders: The filing provides transparency on a significant shareholder's stake, which can influence market perception.
• Management of ClearPoint Neuro, Inc.: Awareness of MAK Capital's holdings may inform strategic discussions regarding shareholder relations.

Next Steps

• MAK Capital entities will continue to hold their shares in ClearPoint Neuro, Inc.
• Future filings will be made if there are material changes in beneficial ownership.

Key Dates

Keywords

ClearPoint Neuro, MAK Capital, Schedule 13G, Beneficial Ownership, Institutional Investor, Common Stock, SEC Filing, Investment Management